Genomenon - About the company
Genomenon is a series C company based in Ann Arbor (United States), founded in 2014 by Steve Schwartz. It operates as a Provider of software, data, and services for genomic information analysis. Genomenon has raised $42.9M in funding from investors like Michigan Rise, Beringea and Broadoak Capital Partners. The company has 689 active competitors, including 156 funded and 105 that have exited. Its top competitors include companies like DNAnexus, Geneoscopy and Fabric Genomics.
Company Details
Provider of software, data, and services for genomic information analysis. The company offers platforms for germline and somatic variant interpretation. It facilitates access to article information on variants and curated germline variant content. The cancer knowledgebase interprets cancer variants, connecting them to therapies and clinical trials.
- Website
- www.genomenon.com
- Social
- Email ID
- *****@genomenon.com
- Registered Address
- 3135 S. State St. Ste 350BR, Ann Arbor, MI 48108, US
Key Metrics
Founded Year
2014
Location
Ann Arbor, United States
Stage
Series C
Total Funding
$42.9M in 14 rounds
Latest Funding Round
Investors
Ranked
25th among 689 active competitors
Employee Count
140 as on Sep 30, 2026
Investment & Acquisitions
Legal entities associated with Genomenon
Genomenon is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Genomenon, Inc. CIN: 20191404253 , United States, Active | May 14, 2019 | - | - | - |
Sign up to download Genomenon's company profile
Genomenon's funding and investors
Genomenon has raised a total funding of $42.9M over 14 rounds. Its first funding round was on Aug 14, 2015. Genomenon has 20 institutional investors and 1 angel investor.
Here is the list of recent funding rounds of Genomenon:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 15, 2026 | 2034170 | Series C | 8534536 | 7740086 | 5146134 | 5883712 |
May 01, 2024 | 6073543 | Series B | 5109298 | 5817941 | 1082816 | 7692775 |
Mar 10, 2022 | 5459409 | Series B | 9822051 | 3800955 |
Access funding benchmarks and valuations. Sign up today!View details of Genomenon's funding rounds and investors
Genomenon's founders and board of directors
Founder? Claim ProfileThe founders of Genomenon is Steve Schwartz.
Here are the details of Genomenon's key team members:
- Steve Schwartz: Co-founder &CTO of Genomenon. They serve on the board of 1 company.
- Mark Kiel: CEO of Genomenon. Contact Info: 1 email address
View details of Genomenon's Founder profiles and Board Members
Genomenon's employee count trend
Genomenon has 140 employees as of Sep 26. Here is Genomenon's employee count trend over the years:
Uncover Genomenon's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Genomenon's Competitors and alternates
Top competitors of Genomenon include DNAnexus, Geneoscopy and Fabric Genomics. Here is the list of Top 10 competitors of Genomenon, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  DNAnexus 2009, Mountain View (United States), Series H | Provider of cloud-based genome informatics & data management platform | $473M | 71/100 | |
2nd | Geneoscopy 2015, St. Louis (United States), Series C | Developer of non-invasive biomarker tests for colorectal cancer | $219M | 67/100 | |
3rd | Fabric Genomics 2009, Oakland (United States), Acquired | AI-based disease diagnosis and genomic analysis tool for providers | $32.8M | 67/100 | |
4th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 66/100 | |
5th | Intellia Therapeutics 2014, Cambridge (United States), Public | Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases | $85M | 66/100 | |
6th |  Twin Strand Bio 2015, Seattle (United States), Series B | Developer of DNA sequencing technology to identify genomic mutations | $84M | 66/100 | |
7th |  Basecamp Research 2019, London (United Kingdom), Series B | Biotechnology company using AI to explore undiscovered biology for applications in pharma, food, and industry | $85M | 64/100 | |
8th |  Deep Genomics 2014, Toronto (Canada), Series C | AI-powered platform for RNA biology to accelerate genetic therapy discovery | $238M | 62/100 | |
9th |  UniQure 1998, Amsterdam (Netherlands), Public | Developer of gene-based therapies for patients with genetic or acquired diseases | $111M | 62/100 | |
10th | GenSight Biologics 2011, Paris (France), Public | Developer of viral vector-based gene therapies for retinal neurodegenerative diseases | $76.6M | 61/100 | |
25th | Genomenon 2014, Ann Arbor (United States), Series C | Provider of software, data, and services for genomic information analysis | $42.9M | 46/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Genomenon's competitors? Click here to see the top ones
Genomenon's Investments and acquisitions
Genomenon has acquired Boston Genetics. Genomenon has not made any investments as of now.Reports related to Genomenon
Here is the latest report on Genomenon's sector:
News related to Genomenon
Filter this listMedia has covered Genomenon for 1 event in last 1 year, It was about partnerships.
•
Genomenon partners with Compass Bioinformatics to transform genomic diagnostics in the US and JapanPR Newswire•Sep 23, 2025•Kangba Bio Information, Genomenon
•
Golden Helix and Genomenon Announce Strategic Partnership to Advance Clinical DiagnosticsPR Newswire•Sep 02, 2025•Golden Helix, Genomenon
•
Genomenon and UCB Partner to Advance Thymidine Kinase 2 Deficiency Awareness and DiagnosisBenzinga•Jul 09, 2025•Genomenon, UCB
•
Intelliseq Integrates Genomenon's Cancer Knowledgebase into iFlow Platform to Advance Somatic Variant InterpretationPR Newswire•Jun 18, 2025•Intelliseq, Genomenon
•
GenomOncology and Genomenon Partner to Enhance Germline Variant Classification and Genomic ReportingBenzinga•Nov 07, 2024•GenomOncology, Genomenon
•
Genomenon Achieves Critical Milestone with Half of Clinical Exome CuratedPRWeb•Jun 20, 2024•Genomenon
•
Genomenon has filed a notice of an exempt offering of securities to raise $6 Million in New Equity Investment.intelligence360•Jun 03, 2024•Genomenon
•
•
Genomenon Launches Classification Service, Medidata’s New Research Alliance, New Devices, Platforms, MoreBio-IT World•Dec 28, 2023•Genomenon
•
Genomenon Acquires Boston Genetics to Accelerate Curation of Human GenomePRWeb•Jun 27, 2023•Genomenon, Boston Genetics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Genomenon
Explore our recently published companies
- La Super Agence - France based, 2014 founded, Unfunded company
- Feedproducts - Madison based, 1945 founded, Unfunded company
- Alternative Funding - Denver based, 2015 founded, Unfunded company
- Saltlicks - United Kingdom based, Unfunded company
- H Designs - Unfunded company
- Comm Butler - Zurich based, Public company
